Article

Study Identifies Why Passive Smoking Promotes Tumor Growth

Toxin produced by cigarette smoke accelerates the growth of tumors.

Passive smoking accounts for an estimated 600,000 deaths per year worldwide, according to the World Health Organization (WHO). In a new study published by Science Reports, investigators found that the organic compound found in cigarette smoke promotes tumor growth.

While smoking a cigarette, the toxin acrolein (acrylic aldehyde) is released into the atmosphere via sidestream smoke.

“Anyone who has ever sat in a smoky pub has breathed it in—–but what worries us more is long-term profession exposure in smoking establishments, as well as the exposure of children and family members in the home of smokers or in the car, where domestic pets are frequently also exposed,” said lead investigator Erika Jensen-Jarolim and lead author Franziska Roth-Walter.

In addition to smoking, acrolein is also produced when vegetable or animal fats are overheated, by burning of printer inks, and from biodiesel or wax.

The results of the study showed that acrolein suppresses the immune system, causing damage to genetic material, and inhibits the body’s natural immune response via regulatory T cells, resulting in the acceleration of tumor growth.

“Inhalation is not the only relevant incorporation pathway,” said Jensen-Jarolim. “Acrolein can stick to anything, such as dinner plates, clothing or curtains and so can be incorporated much later on, via the skin, for example. It is therefore particularly important to protect children and pregnant women, especially in the domestic situation—–and this can only be done by completely eliminating any contact with cigarette smoke or its residues.”

Using animal models, the investigators found that acrolein did have a very slight beneficial effect on the immune system. Because acrolein suppresses the immune response, smokers are much less susceptible to allergies.

The findings indicate that acrolein is Janus-face, meaning it has 2 different faces.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards